Given that elevated levels of TAPBP AAb after treatment have shown prognostic value in immunotherapy and the positive association between TAPBP mRNA and PD-L1 mRNA, we propose that the increase in TAPBP AAb levels in responders after reshaping the tumor microenvironment is indicative of superior treatment outcomes. The gene discussed is TAPBP; the disease is neoplasm.